Nuclear receptors are amongst the most successful therapeutic targets in oncology, with small molecule inhibitors of estrogen receptor (ER) and androgen receptor (AR) improving survival in breast and prostate cancers (Fisher et al., 1996; Beer et al., 2014). Here, AR is linked to prostate cancer.